| Title: | REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy study |
| Author(s): | Bradley C; Hee SW; Andronis L; Persaud K; Hull MA; Todd J; Taylor-Phillips S; Smith S; Constable R; Waugh N; Arasaradnam RP; Group RS; |
| Address: | "Research & Development, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK Christopher.Bradley@uhcw.nhs.uk. Warwick Clinical Trials Unit, University of Warwick, Coventry, UK. Department of Chemical Engineering, The University of Manchester, Manchester, UK. School of Medicine, University of Leeds, Leeds, UK. Research & Development, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. Bowel Cancer Screening Hub, NW Bowel Cancer Screening Hub, Hospital of St. Cross, Rugby, UK. Warwick Medical School, University of Warwick, Coventry, UK" |
| DOI: | 10.1136/bmjopen-2021-058559 |
| ISSN/ISBN: | 2044-6055 (Electronic) 2044-6055 (Linking) |
| Abstract: | "INTRODUCTION: Demand for colonoscopies and CT colonography (CTC) is exceeding capacity in National Health Service Trusts. In many patients colonoscopies and CTCs show no significant bowel disease (SBD). Faecal Immunochemical Testing (FIT) is being introduced to prioritise patients for colonoscopies but is insufficient to identify non-SBD patients meaning colonoscopy and CTC demand remains high. The REducing Colonoscopies in patients without significant bowEl DiseasE (RECEDE) study aims to test urine volatile organic compound (VOC) analysis alongside FIT to improve detection of SBD and to reduce the number of colonoscopies and CTCs. METHODS AND ANALYSIS: This is a multicentre, prospective diagnostic accuracy study evaluating whether stool FIT plus urine VOC compared with stool FIT alone improves detection of SBD in patients referred for colonoscopy or CTC due to persistent lower gastrointestinal symptoms. To ensure SBD is not missed, the dual test requires a high sensitivity, set at 97% with 95% CI width of 5%. Our assumption is that to achieve this sensitivity requires 200 participants with SBD. Further assuming 19% of all participants will have SBD and 55% of all participants will return both stool and urine samples we will recruit 1915 participants. The thresholds for FIT and VOC results diagnosing SBD have been pre-set. If either FIT or VOC exceeds the respective threshold, the participant will be classed as having suspected SBD. As an exploratory analysis we will be testing different thresholds. The reference comparator will be a complete colonoscopy or CTC. Secondary outcomes will look at optimising the FIT and VOC thresholds for SBD detection. An economic evaluation, using a denovo decision analytic model, will be carried out determine the costs, benefits and overall cost-effectiveness of FIT +VOC vs FIT followed by colonoscopy. ETHICS AND DISSEMINATION: Ethical approval was obtained by Liverpool Central Research Ethics Committee (20/NW/0346). TRIAL REGISTRATION NUMBER: RECEDE is registered on Clinicaltrials.gov NCT04516785 & ISRCTN14982373. This protocol was written and published before results of the trial were available" |
| Keywords: | *Colonoscopy/methods Humans Occult Blood Prospective Studies Sensitivity and Specificity *State Medicine Colorectal surgery Computed tomography Endoscopy; |
| Notes: | "MedlineBradley, Christopher Hee, Siew Wan Andronis, Lazaros Persaud, Krishna Hull, Mark A Todd, John Taylor-Phillips, Sian Smith, Steve Constable, Rachel Waugh, Norman Arasaradnam, Ramesh P eng DH_/Department of Health/United Kingdom Research Support, Non-U.S. Gov't England 2022/04/01 BMJ Open. 2022 Mar 30; 12(3):e058559. doi: 10.1136/bmjopen-2021-058559" |
